MitoQ for Early-phase Schizophrenia-spectrum Disorder and Mitochondrial Dysfunction
Phase 2/3
100
about 2.7 years
18–35
2 sites in CT, MA
About this study
Researchers are testing whether MitoQ, an antioxidant, improves cognition in people with early schizophrenia-spectrum disorders who have mitochondrial dysfunction. The trial will last 974 days and involve taking MitoQ or a placebo once daily for 12 weeks. Participants will also attend trial visits every four weeks.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take MitoQ
- 2.Take Placebo
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
dietary supplement
Primary: Change from baseline in the MATRICS Consensus Cognitive Battery (MCCB) composite score at week 12
Secondary: Change from baseline in the Clinical Global Impressions Severity (CGI-S) scale score at week 12, Change from baseline in the Global Assessment of Functioning (GAF) score at week 12, Change from baseline in the MATRICS Consensus Cognitive Battery (MCCB) attention/vigilance score at week 12, Change from baseline in the MATRICS Consensus Cognitive Battery (MCCB) reasoning and problem solving score at week 12, Change from baseline in the MATRICS Consensus Cognitive Battery (MCCB) social cognition score at week 12, Change from baseline in the MATRICS Consensus Cognitive Battery (MCCB) speed of processing score at week 12, Change from baseline in the MATRICS Consensus Cognitive Battery (MCCB) verbal learning score at week 12, Change from baseline in the MATRICS Consensus Cognitive Battery (MCCB) visual learning score at week 12
Psychiatry / Mental Health